Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by persistent hyperglycaemia with significant morbidity and mortality rates. Currently, metformin is a drug used as first-line therapy during the management of T2DM patients. Despite metformin's effectiveness and potency in lowering blood sugar levels, metformin had poor bioavailability and was prescribed in high doses of 500/1000 mg daily, which subsequently led to undesirable side effects. A high-dose regimen also needs a bigger pill size, which decreases patient compliance in dysphagic patients. To address these issues, many studies have attempted to develop metformin-based orally disintegrating tablets (ODTs) that possess rapid disintegration and dissolution properties to improve patient compliance and drug bioavailability. The present review aimed to highlight the recent studies on development and critical insights into addressing the challenges pertaining to designing the optimized formulation of metformin ODTs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.